|
⚲
|
| Keyboard |
| Ra Capital Management LLC | |
|---|---|
| Firm | RA Capital Management LP |
| Address | 20 Park Plaza, Suite 1200 Ugland House, South Church Street Boston, MA 02116 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| RA Capital Management LP | |||||
| RA Capital Healthcare Fund LP | 021-100507 | Promoter | 2,361.1 M | 14.53 B | |
| RA Capital Healthcare Fund LP | 021-74043 | Executive Officer | 4,020.2 M | ||
| RA Capital Healthcare Fund II LP | 021-101432 | Executive Officer | 2.1 M | ||
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Wave Life Sciences Pte Ltd WVE
Ordinary Shares
|
2026-03-30 | Buy | 971,091 | $6.50 | 6,312,092 |
|
Mineralys Therapeutics Inc MLYS
Common Stock
|
2026-03-30 | Buy | 58,300 | $24.16 | 1,408,528 |
|
Mineralys Therapeutics Inc MLYS
Common Stock
|
2026-03-27 | Buy | 310,700 | $23.67 | 7,354,269 |
|
Wave Life Sciences Pte Ltd WVE
Ordinary Shares
|
2026-03-27 | Buy | 2,495,623 | $6.43 | 16,046,856 |
|
Wave Life Sciences Pte Ltd WVE
Ordinary Shares
|
2026-03-26 | Buy | 4,954,558 | $6.06 | 30,024,621 |
|
Wave Life Sciences Pte Ltd WVE
Ordinary Shares
|
2026-03-26 | Buy | 351,224 | $6.38 | 2,240,809 |
|
Acumen Pharmaceuticals Inc ABOS
Common Stock
|
2026-03-16 | Grant | 6,060,606 | $3.30 | 20,000,000 |
|
Bicara Therapeutics Inc BCAX
Common Stock
|
2026-02-26 | Buy | 300,000 | $16.00 | 4,800,000 |
|
Bicara Therapeutics Inc BCAX
Pre-Funded Warrant (Right to Buy) · derivative
|
2026-02-26 | Buy | 2,200,000 | $16.00 | 35,200,000 |
|
Mineralys Therapeutics Inc MLYS
Common Stock
|
2026-02-19 | Grant | 6,200 | $0.00 | |
|
Mineralys Therapeutics Inc MLYS
Stock Option (Right to Buy) · derivative
|
2026-02-19 | Grant | 8,300 | $0.00 | |
|
Evommune Inc EVMN
Common Stock
|
2026-02-17 | Grant | 35,868 | $27.88 | 1,000,000 |
|
SpyGlass Pharma Inc SGP
Series C-2 Preferred Stock · derivative
|
2026-02-09 | Conversion | 767,294 | ||
|
SpyGlass Pharma Inc SGP
Common Stock
|
2026-02-09 | Buy | 3,441,966 | $16.00 | 55,071,456 |
|
SpyGlass Pharma Inc SGP
Series C-2 Preferred Stock · derivative
|
2026-02-09 | Conversion | 1,150,941 | ||
|
SpyGlass Pharma Inc SGP
Common Stock
|
2026-02-09 | Buy | 248,034 | $16.00 | 3,968,544 |
|
SpyGlass Pharma Inc SGP
Common Stock
|
2026-02-09 | Conversion | 1,806,644 | ||
|
SpyGlass Pharma Inc SGP
Series D Preferred Stock · derivative
|
2026-02-09 | Conversion | 222,591 | ||
|
SpyGlass Pharma Inc SGP
Series D Preferred Stock · derivative
|
2026-02-09 | Conversion | 272,056 | ||
|
SpyGlass Pharma Inc SGP
Common Stock
|
2026-02-09 | Conversion | 2,524,473 | ||
| showing 20 of 200 most recent transactions | |||||